Deserpidine (free base)| CAS#131-01-1 (free base)| MedKoo

MedKoo Cat#: 317650 | Name: Deserpidine (free base)

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Deserpidine (free base) is an antihypertensive drug related to reserpine which occurs naturally in Rauwolfia canescens. Deserpidine is a competitive inhibitor of the angiotensin converting enzyme (ACE). By competing with angiotensin I for ACE, deserpidine blocks the conversion of angiotensin I to angiotensin II, which is a potent vasoconstrictor. Reduced level of serum angiotensin II causes a decrease in blood pressure. Deserpidine also decreases angiotensin II-induced aldosterone secretion by the adrenal cortex.

Chemical Structure

Deserpidine (free base)

CAS#131-01-1 (free base)

Theoretical Analysis

MedKoo Cat#: 317650

Name: Deserpidine (free base)

CAS#: 131-01-1 (free base)

Chemical Formula: C32H38N2O8

Exact Mass: 578.2628

Molecular Weight: 578.65

Elemental Analysis: C, 66.42; H, 6.62; N, 4.84; O, 22.12

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

6033-69-8 (HCl) 131-01-1 (free base)

Synonym

Deserpidine (free base); Harmonyl; Raunormine; Recanescin; Canescine; Desepridine

IUPAC/Chemical Name

methyl (1R,15S,17R,18R,19S,20S)-18-methoxy-17-(3,4,5-trimethoxybenzoyloxy)-3,13-diazapentacyclo[11.8.0.02,10.04,9.015,20]henicosa-2(10),4,6,8-tetraene-19-carboxylate

InChi Key

CVBMAZKKCSYWQR-UHFFFAOYSA-N

InChi Code

InChI=1S/C32H38N2O8/c1-37-24-12-17(13-25(38-2)29(24)39-3)31(35)42-26-14-18-16-34-11-10-20-19-8-6-7-9-22(19)33-28(20)23(34)15-21(18)27(30(26)40-4)32(36)41-5/h6-9,12-13,18,21,23,26-27,30,33H,10-11,14-16H2,1-5H3

SMILES Code

COC1C(CC2CN3CCC4=C(C3CC2C1C(=O)OC)NC5=CC=CC=C45)OC(=O)C6=CC(=C(C(=C6)OC)OC)OC

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 578.65 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Zhang H, Zhong D, Zhang Z, Dai X, Chen X. Liquid chromatography/tandem mass spectrometry method for the quantification of deserpidine in human plasma: Application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Oct 1;877(27):3221-5. doi: 10.1016/j.jchromb.2009.06.005. Epub 2009 Jun 10. PubMed PMID: 19620026. 2: Varchi G, Battaglia A, Samorì C, Baldelli E, Danieli B, Fontana G, Guerrini A, Bombardelli E. Synthesis of deserpidine from reserpine. J Nat Prod. 2005 Nov;68(11):1629-31. PubMed PMID: 16309312. 3: Fulton SC, Healy MD. Comparison of the effectiveness of deserpidine, reserpine, and alpha-methyltyrosine on brain biogenic amines. Fed Proc. 1976 Dec;35(14):2558-62. PubMed PMID: 11134. 4: Plotnikoff NP, Kastin AJ, Anderson MS, Schally AV. Deserpidine antagonism by a tripeptide, L-prolyl-L-leucyglycinamide. Neuroendocrinology. 1973;11(1):67-71. PubMed PMID: 4633626. 5: Everett GM, Borcherding J, Morse P. Effect of deserpidine and pargyline on the levels of biogenic amines in brain, liver and heart of mice. Res Commun Chem Pathol Pharmacol. 1972 Mar;3(2):245-8. PubMed PMID: 4679851. 6: da Rocha AL, Saldanha RV. [Clinical laboratory study of essential hypertension patients treated with a methylclothiazide deserpidine combination]. Hospital (Rio J). 1968 Oct;74(4):1299-304. Portuguese. PubMed PMID: 5304160. 7: Hutchison JC. Pargyline hydrochloride, methyclothiazide, and deserpidine in therapy of hypertension and prevention of "cheese reaction". Curr Ther Res Clin Exp. 1968 Mar;10(3):128-35. PubMed PMID: 4967000. 8: Shafei AZ, Abaza HH. Clinical and laboratory observations on the use of a combination of methyclothiazide and deserpidine in treatment of essential hypertension. J Egypt Med Assoc. 1968;51(1):48-56. PubMed PMID: 4876817. 9: Gaskell AJ, Joule JA. The acid catalysed C3 epimerization of reserpine and deserpidine. Tetrahedron. 1967 Oct;23(10):4053-63. PubMed PMID: 6065625. 10: de Faria CV. [Treatment of essential arterial hypertension by the methyclothiazide-deserpidine]. Rev Bras Med. 1967 May;24(5):331-3. Portuguese. PubMed PMID: 5603874.